Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Øyvind Palm is active.

Publication


Featured researches published by Øyvind Palm.


Annals of the Rheumatic Diseases | 2015

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

Suzana Jordan; Jörg H W Distler; Britta Maurer; Dörte Huscher; Jacob M. van Laar; Yannick Allanore; Oliver Distler; Tore K. Kvien; Paolo Airò; Juan José Alegre Sancho; Lidia Ananjeva; Codrina Michaela Ancuta; Martin Aringer; Alexandra Balbir-Gurman; Francesco Paolo Cantatore; Paola Caramaschi; Emmanuel Chatelus; Veronica Codullo; Dominique Farge-Bancel; Armando Gabrielli; Jörg Henes; Ilka Herrgott; Florenzo Iannone; Francesca Ingegnoli; Esthela Loyo; Marco Matucci-Cerinic; Walid Ahmed Abdel Atty Mohamed; Ulf Müller-Ladner; Øyvind Palm; Sergiu Popa

Objectives To assess the effects of Rituximab (RTX) on skin and lung fibrosis in patients with systemic sclerosis (SSc) belonging to the European Scleroderma Trial and Research (EUSTAR) cohort and using a nested case-control design. Methods Inclusion criteria were fulfilment of American College of Rheumatology classification criteria for SSc, treatment with RTX and availability of follow-up data. RTX-treated patients were matched with control patients from the EUSTAR database not treated with RTX. Matching parameters for skin/lung fibrosis were the modified Rodnan Skin Score (mRSS), forced vital capacity (FVC), follow-up duration, scleroderma subtype, disease duration and immunosuppressive co-treatment. The primary analysis was mRSS change from baseline to follow-up in the RTX group compared with the control group. Secondary analyses included change of FVC and safety measures. Results 63 patients treated with RTX were included in the analysis. The case-control analysis in patients with severe diffuse SSc showed that mRSS changes were larger in the RTX group versus matched controls (N=25; −24.0±5.2% vs −7.7±4.3%; p=0.03). Moreover, in RTX-treated patients, the mean mRSS was significantly reduced at follow-up compared with baseline (26.6±1.4 vs 20.3±1.8; p=0.0001). In addition, in patients with interstitial lung disease, RTX prevented significantly the further decline of FVC compared with matched controls (N=9; 0.4±4.4% vs −7.7±3.6%; p=0.02). Safety measures showed a good profile consistent with previous studies in autoimmune rheumatic diseases. Conclusions The comparison of RTX treated versus untreated matched-control SSc patients from the EUSTAR cohort demonstrated improvement of skin fibrosis and prevention of worsening lung fibrosis, supporting the therapeutic concept of B cell inhibition in SSc.


PLOS Genetics | 2011

Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy

Olga Y. Gorlova; José Martín; Blanca Rueda; Bobby P. C. Koeleman; Jun Ying; María Teruel; Lina Marcela Diaz-Gallo; Jasper Broen; Madelon C. Vonk; Carmen P. Simeon; Behrooz Z. Alizadeh; Marieke J. H. Coenen; Alexandre E. Voskuyl; Annemie J. Schuerwegh; Piet L. C. M. van Riel; Marie Vanthuyne; Ruben van 't Slot; Annet Italiaander; Roel A. Ophoff; Nicolas Hunzelmann; Vicente Fonollosa; Norberto Ortego-Centeno; Miguel A. González-Gay; Francisco J. García-Hernández; María F. González-EscribanoMarí; Paolo Airò; Jacob M van Laar; Jane Worthington; Roger Hesselstrand; Vanessa Smith

The aim of this study was to determine, through a genome-wide association study (GWAS), the genetic components contributing to different clinical sub-phenotypes of systemic sclerosis (SSc). We considered limited (lcSSc) and diffuse (dcSSc) cutaneous involvement, and the relationships with presence of the SSc-specific auto-antibodies, anti-centromere (ACA), and anti-topoisomerase I (ATA). Four GWAS cohorts, comprising 2,296 SSc patients and 5,171 healthy controls, were meta-analyzed looking for associations in the selected subgroups. Eighteen polymorphisms were further tested in nine independent cohorts comprising an additional 3,175 SSc patients and 4,971 controls. Conditional analysis for associated SNPs in the HLA region was performed to explore their independent association in antibody subgroups. Overall analysis showed that non-HLA polymorphism rs11642873 in IRF8 gene to be associated at GWAS level with lcSSc (P = 2.32×10−12, OR = 0.75). Also, rs12540874 in GRB10 gene (P = 1.27 × 10−6, OR = 1.15) and rs11047102 in SOX5 gene (P = 1.39×10−7, OR = 1.36) showed a suggestive association with lcSSc and ACA subgroups respectively. In the HLA region, we observed highly associated allelic combinations in the HLA-DQB1 locus with ACA (P = 1.79×10−61, OR = 2.48), in the HLA-DPA1/B1 loci with ATA (P = 4.57×10−76, OR = 8.84), and in NOTCH4 with ACA P = 8.84×10−21, OR = 0.55) and ATA (P = 1.14×10−8, OR = 0.54). We have identified three new non-HLA genes (IRF8, GRB10, and SOX5) associated with SSc clinical and auto-antibody subgroups. Within the HLA region, HLA-DQB1, HLA-DPA1/B1, and NOTCH4 associations with SSc are likely confined to specific auto-antibodies. These data emphasize the differential genetic components of subphenotypes of SSc.


Human Molecular Genetics | 2012

A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations

Lara Bossini-Castillo; José Martín; Jasper Broen; Olga Y. Gorlova; Carmen P. Simeon; Lorenzo Beretta; Madelon C. Vonk; José Luis Callejas; I. Castellví; Patricia Carreira; Francisco J. García-Hernández; Mónica Fernández Castro; Marieke J. H. Coenen; Gabriela Riemekasten; Torsten Witte; Nicolas Hunzelmann; Alexander Kreuter; Jörg H W Distler; Bobby P. C. Koeleman; Alexandre E. Voskuyl; Annemie J. Schuerwegh; Øyvind Palm; Roger Hesselstrand; Annika Nordin; Paolo Airò; Claudio Lunardi; Raffaella Scorza; Paul G. Shiels; Jacob M van Laar; Ariane L. Herrick

A single-nucleotide polymorphism (SNP) at the IL12RB2 locus showed a suggestive association signal in a previously published genome-wide association study (GWAS) in systemic sclerosis (SSc). Aiming to reveal the possible implication of the IL12RB2 gene in SSc, we conducted a follow-up study of this locus in different Caucasian cohorts. We analyzed 10 GWAS-genotyped SNPs in the IL12RB2 region (2309 SSc patients and 5161 controls). We then selected three SNPs (rs3790567, rs3790566 and rs924080) based on their significance level in the GWAS, for follow-up in an independent European cohort comprising 3344 SSc and 3848 controls. The most-associated SNP (rs3790567) was further tested in an independent cohort comprising 597 SSc patients and 1139 controls from the USA. After conditional logistic regression analysis of the GWAS data, we selected rs3790567 [P(MH)= 1.92 × 10(-5) odds ratio (OR) = 1.19] as the genetic variant with the firmest independent association observed in the analyzed GWAS peak of association. After the first follow-up phase, only the association of rs3790567 was consistent (P(MH)= 4.84 × 10(-3) OR = 1.12). The second follow-up phase confirmed this finding (P(χ2) = 2.82 × 10(-4) OR = 1.34). After performing overall pooled-analysis of all the cohorts included in the present study, the association found for the rs3790567 SNP in the IL12RB2 gene region reached GWAS-level significant association (P(MH)= 2.82 × 10(-9) OR = 1.17). Our data clearly support the IL12RB2 genetic association with SSc, and suggest a relevant role of the interleukin 12 signaling pathway in SSc pathogenesis.


Rheumatology | 2013

Clinical pulmonary involvement in primary Sjögren’s syndrome: prevalence, quality of life and mortality—a retrospective study based on registry data

Øyvind Palm; Torhild Garen; Tone Berge Enger; Janicke Liaaen Jensen; May-Brit Lund; Trond Mogens Aaløkken; Jan Tore Gran

OBJECTIVE The aim of the present study was to describe the prevalence of clinical pulmonary manifestations in primary SS (pSS), and based on registry data, to assess quality of life (QoL) and mortality in these patients. METHODS Patients with pSS consecutively included in the Norwegian systemic CTD and vasculitis registry (NOSVAR) were investigated for pulmonary manifestations when presenting with clinical pulmonary symptoms. Pulmonary involvement was defined as typical abnormalities identified with high-resolution CT (HRCT) and/or pulmonary function tests (PFTs). RESULTS Among patients referred from our primary area, Oslo (n = 117), lung involvement was found in 26 patients (22%). In our total cohort (n = 216), 59 patients (27%) were affected. A higher rate of pulmonary complications and trends towards longer disease duration and higher age indicated a selection of more complicated cases referred from outside our primary area. Abnormal HRCTs were found in 50 patients (23%) and PFTs in 34 patients (16%). The Medical Outcomes Study 36-Item Short-Form Health Survey Physical Functioning subscore, was significantly reduced in patients with lung involvement (P = 0.03). Furthermore, a 4-fold increased risk of dying after 10 years of disease among patients with lung involvement (n = 10, 17%) compared with those without lung involvement (n = 7, 4.5%) (P = 0.002) was found. CONCLUSION We found a high population-based prevalence of clinical pulmonary involvement (22%) among patients with pSS. Moreover, patients with lung involvement had reduced QoL represented by the subscale Physical Functioning, and mortality was increased.


Annals of the Rheumatic Diseases | 2011

A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort

Lara Bossini-Castillo; Jasper Broen; Carmen P. Simeon; Lorenzo Beretta; Madelon C. Vonk; Norberto Ortego-Centeno; Gerard Espinosa; Patricia Carreira; María Teresa Camps; Nuria Navarrete; María Francisca González-Escribano; Esther Vicente-Rabaneda; Luis A. García Rodríguez; Carlos Tolosa; José Andrés Román-Ivorra; Inmaculada Gómez-Gracia; Francisco J. García-Hernández; I. Castellví; María Gallego; Antonio Fernández-Nebro; Rosa Garcia-Portales; María Victoria Egurbide; Vicente Fonollosa; Paloma García de la Peña; Ana Pros; Miguel A. González-Gay; Roger Hesselstrand; Gabriela Riemekasten; Torsten Witte; Marieke J. H. Coenen

Objectives The aim of this study was to confirm the influence of TNFSF4 polymorphisms on systemic sclerosis (SSc) susceptibility and phenotypic features. Methods A total of 8 European populations of Caucasian ancestry were included, comprising 3014 patients with SSc and 3125 healthy controls. Four genetic variants of TNFSF4 gene promoter (rs1234314, rs844644, rs844648 and rs12039904) were selected as genetic markers. Results A pooled analysis revealed the association of rs1234314 and rs12039904 polymorphisms with SSc (OR 1.15, 95% CI 1.02 to 1.31; OR 1.18, 95% CI 1.08 to 1.29, respectively). Significant association of the four tested variants with patients with limited cutaneous SSc (lcSSc) was revealed (rs1234314 OR 1.22, 95% CI 1.07 to 1.38; rs844644 OR 0.91, 95% CI 0.83 to 0.99; rs844648 OR 1.10, 95% CI 1.01 to 1.20 and rs12039904 OR 1.20, 95% CI 1.09 to 1.33). Association of rs1234314, rs844648 and rs12039904 minor alleles with patients positive for anti-centromere antibodies (ACA) remained significant (OR 1.23, 95% CI 1.10 to 1.37; OR 1.12, 95% CI 1.01 to 1.25; OR 1.22, 95% CI 1.07 to 1.38, respectively). Haplotype analysis confirmed a protective haplotype associated with SSc, lcSSc and ACA positive subgroups (OR 0.88, 95% CI 0.82 to 0.96; OR 0.88, 95% CI 0.80 to 0.96; OR 0.86, 95% CI 0.77 to 0.97, respectively) and revealed a new risk haplotype associated with the same groups of patients (OR 1.14, 95% CI 1.03 to 1.26; OR 1.20, 95% CI 1.08 to 1.35; OR 1.23, 95% CI 1.07 to 1.42, respectively). Conclusions The data confirm the influence of TNFSF4 polymorphisms in SSc genetic susceptibility, especially in subsets of patients positive for lcSSc and ACA.


Scandinavian Journal of Gastroenterology | 2015

Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: results from a prospective, population-based European inception cohort

Rune Isene; Tomm Bernklev; Ole Høie; Pia Munkholm; Epameonondas Tsianos; R.W. Stockbrügger; Selwyn Odes; Øyvind Palm; Milada Cvancarova Småstuen; Bjørn Moum

Abstract Background. In chronic inflammatory bowel disease (IBD) (Crohn’s disease [CD] and ulcerative colitis [UC]), symptoms from outside the gastrointestinal tract are frequently seen, and the joints, skin, eyes, and hepatobiliary area are the most usually affected sites (called extraintestinal manifestations [EIM]). The reported prevalence varies, explained by difference in study design and populations under investigation. The aim of our study was to determine the prevalence of EIM in a population-based inception cohort in Europe and Israel. Methods. IBD patients were incepted into a cohort that was prospectively followed from 1991 to 2004. A total of 1145 patients were followed for 10 years. Results. The cumulative prevalence of first EIM was 16.9% (193/1145 patients) over a median follow-up time of 10.1 years. Patients with CD were more likely than UC patients to have immune-mediated (arthritis, eye, skin, and liver) manifestations: 20.1% versus 10.4% (p < 0.001). Most frequently seen was arthritis which was significantly more common in CD (12.9%) than in UC (8.1%), p = 0.01. Pan-colitis compared to proctitis in UC increased the risk of EIM. Conclusion. In a European inception cohort, EIMs in IBD were consistent with that seen in comparable studies. Patients with CD are twice as likely as UC patients to experience EIM, and more extensive distribution of inflammation in UC increases the risk of EIM.


Rheumatology | 2013

Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature

Ragnar Gunnarsson; Arne K. Andreassen; Øyvind Molberg; Åse Stavland Lexberg; Kari Time; Alvilde Dhainaut; Liv-Turid Bertelsen; Øyvind Palm; Karen Irgens; Andrea Becker-Merok; Jan Leidulf Nordeide; Villy Johnsen; Sonja Pedersen; Anne Prøven; Lamya Samir Noori Garabet; Torhild Garen; Trond Mogens Aaløkken; Inge-Margrethe Gilboe; Jan Tore Gran

OBJECTIVES The aim of this study was to assess the overall prevalence of pulmonary hypertension (PH) in an unselected MCTD cohort and review the current knowledge with a systematic database search. METHODS A nationwide multicentre cohort of 147 adult MCTD patients were initially screened for PH by echocardiography, high-resolution computed tomography (HRCT), pulmonary function tests and N-terminal pro-brain natriuretic peptide (NT-proBNP) and then followed up for a mean of 5.6 years. Right-sided heart catheterization was performed when estimated pulmonary artery systolic pressure was >40 mmHg on echocardiography. PH was diagnosed according to the 2009 European Society of Cardiology and European Respiratory Society guidelines. RESULTS At inclusion, 2.0% (3/147) had established PH. Two additional PH patients were identified during follow-up, giving a total PH frequency in the cohort of 3.4% (5/147). All five had elevated serum NT-proBNP. Two had isolated pulmonary arterial hypertension (PAH) and three PH associated with interstitial lung disease (PH-ILD). Three PH patients died during follow-up. Nine other patients in the cohort also died, but none of them had echocardiographic signs of PH prior to death. CONCLUSION The data from the current unselected MCTD cohort suggest that the prevalence of PH is much lower than expected from previous studies but confirm the seriousness of the disease complication.


European Journal of Oral Sciences | 2011

Oral distress in primary Sjögren’s syndrome: implications for health-related quality of life

Tone Berge Enger; Øyvind Palm; Torhild Garen; Leiv Sandvik; Janicke Liaaen Jensen

The aims of the study were to evaluate oral distress in patients with primary Sjögrens syndrome (pSS) compared with age- and sex-matched Norwegian normative data, to estimate the occurrence of oral symptoms in pSS, and to evaluate the impact of oral distress on health-related quality of life (HRQoL). The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) was used to assess HRQoL, and the Oral Health Impact Profile 14 (OHIP-14) was used to measure oral distress. Of the 246 pSS patients invited to participate in the study, 177 (72%) responded. Data were analysed for the female participants (n = 163). Significant deviations from normative estimates were found in all OHIP-14 item results, and the findings indicated a high level of oral distress among the pSS patients. Health-related quality of life was decreased among pSS patients, with the largest deviations from normative estimates related to general health and role physical. The patients with high levels of oral distress scored significantly lower than patients with low levels of oral distress in five of the SF-36 subscales, indicating that oral conditions have a marked impact on general quality of life. In conclusion, oral distress in pSS is pronounced and severe, and should receive increased attention with a view to improving the quality of life for these patients.


The Journal of Rheumatology | 2012

Influence of the IL6 Gene in Susceptibility to Systemic Sclerosis

María Carmen Cénit; Carmen P. Simeon; Madelon C. Vonk; José Luis Callejas-Rubio; Gerard Espinosa; Patricia Carreira; F.J. Blanco; Javier Narváez; Carlos Tolosa; José Andrés Román-Ivorra; Inmaculada Gómez-García; Francisco J. García-Hernández; María Gallego; Rosa Garcia Sanchez; María Victoria Egurbide; Vicente Fonollosa; Paloma García de la Peña; Francisco Javier López-Longo; Miguel A. González-Gay; Roger Hesselstrand; Gabriela Riemekasten; Torsten Witte; A.E. Voskuyl; Annemie J. Schuerwegh; Rajan Madhok; Carmen Fonseca; Christopher P. Denton; Annika Nordin; Øyvind Palm; Jacob M. van Laar

Objective. Systemic sclerosis (SSc) is a genetically complex autoimmune disease; the genetic component has not been fully defined. Interleukin 6 (IL-6) plays a crucial role in immunity and fibrosis, both key aspects of SSc. We investigated the influence of IL6 gene in the susceptibility and phenotype expression of SSc. Methods. We performed a large metaanalysis including a total of 2749 cases and 3189 controls from 6 white populations (Germany, The Netherlands, Norway, Spain, Sweden, and United Kingdom). Three IL6 single-nucleotide polymorphisms (SNP; rs2069827, rs1800795, and rs2069840) were selected by SNP tagging and genotyped using TaqMan® allele discrimination technology. Results. Individual SNP metaanalysis showed no evidence of association of the 3 IL6 genetic variants with the global disease. Phenotype analyses revealed a significant association between the minor allele of rs2069840 and the limited cutaneous SSc clinical form (Bonferroni p = 0.036, OR 1.14, 95% CI 1.04–1.25). A trend of association between the minor allele of the rs1800795 and the diffuse cutaneous SSc clinical form was also evident (Bonferroni p = 0.072, OR 0.86, 95% CI 0.77–0.96). In the IL6 allelic combination analyses, the GGC allelic combination rs2069827-rs1800795-rs2069840 showed an association with overall SSc (Bonferroni p = 0.016, OR 1.13, 95% CI 1.04–1.23). Conclusion. Our results suggest that the IL6 gene may influence the development of SSc and its progression.


Annals of the Rheumatic Diseases | 2014

Influence of the IL17A locus in giant cell arteritis susceptibility

Ana Márquez; José Hernández-Rodríguez; Maria C. Cid; Roser Solans; Santos Castañeda; M. E. Fernández-Contreras; M. Ramentol; Inmaculada C. Morado; Javier Narváez; C. Gómez-Vaquero; Víctor Manuel Martínez-Taboada; Norberto Ortego-Centeno; B. Sopeña; Jordi Monfort; María Jesús García-Villanueva; L. Caminal-Montero; E. de Miguel; Ricardo Blanco; Øyvind Palm; Øyvind Molberg; J. Latus; Niko Braun; Frank Moosig; Torsten Witte; Lorenzo Beretta; Alessandro Santaniello; Giulia Pazzola; Luigi Boiardi; Carlo Salvarani; González-Gay Ma

Objective Different lines of evidence have highlighted the role of IL-17A in the inflammatory process occurring in giant cell arteritis (GCA). The aim of the present study was to assess whether the IL17A locus influences GCA susceptibility and its clinical subphenotypes. Methods We carried out a large meta-analysis including a total of 1266 biopsy-proven GCA patients and 3779 healthy controls from four European populations (Spain, Italy, Germany and Norway). Five IL17A polymorphisms (rs4711998, rs8193036, rs3819024, rs2275913 and rs7747909) were selected by tagging and genotyped using TaqMan assays. Allelic combination and dependency tests were also performed. Results In the pooled analysis, two of the five analysed polymorphisms showed evidence of association with GCA (rs2275913: PMH=1.85E−03, OR=1.17 (1.06–1.29); rs7747909: PMH=8.49E–03, OR=1.15 (1.04–1.27)). A clear trend of association was also found for the rs4711998 variant (PMH=0.059, OR=1.11 (1.00–1.23)). An independent effect of rs2275913 and rs4711998 was evident by conditional regression analysis. In addition, the haplotype harbouring the risk alleles better explained the observed association than the polymorphisms independently (likelihood p value <10−05). Conclusions Polymorphisms within the IL17A locus show a novel association with GCA. This finding supports the relevant role of the Th17 cells in this vasculitis pathophysiology.

Collaboration


Dive into the Øyvind Palm's collaboration.

Top Co-Authors

Avatar

Torhild Garen

Oslo University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bjørn Moum

Oslo University Hospital

View shared research outputs
Top Co-Authors

Avatar

Jan Tore Gran

Oslo University Hospital

View shared research outputs
Top Co-Authors

Avatar

Lorenzo Beretta

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marianne Wallenius

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Madelon C. Vonk

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge